Researchers Enhance Breast Cancer Treatment with New Solution

Researchers have identified a potential solution for breast cancer patients who experience inadequate responses to a widely used treatment, tamoxifen. This treatment works by blocking the hormone estrogen from attaching to receptors on cancer cells, which is crucial for limiting cancer growth. However, approximately one-third of patients exhibit low levels of the enzyme CYP2D6, which is necessary for converting tamoxifen into its active form, known as (Z)-endoxifen. This impairment can significantly reduce the treatment’s effectiveness.

While alternative medications, known as aromatase inhibitors, are available for postmenopausal women, younger patients often do not have this option. A new study suggests that administering supplemental (Z)-endoxifen can counteract the insufficient conversion of tamoxifen, thereby enhancing its efficacy. The findings were published in Clinical Cancer Research and were derived from a German study involving 235 patients diagnosed with early-stage hormone-dependent breast cancer.

Study Findings and Implications

In the study, participants were treated with either tamoxifen alone or in combination with (Z)-endoxifen, based on their ability to metabolize tamoxifen effectively. Those receiving the combination therapy achieved blood concentrations of the drug comparable to those in patients with normal metabolism who were treated with tamoxifen alone. The side effects reported were mild and consistent across both groups, indicating a favorable safety profile for the combination treatment.

Dr. Matthias Schwab, the study’s lead researcher at the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology in Stuttgart, emphasized the significance of these findings: “With this approach, we are offering the first effective solution to a long-standing problem: the insufficient effect of tamoxifen in a significant proportion of patients.”

Next Steps in Research

Currently, a mid-stage trial is underway in the United States to further evaluate (Z)-endoxifen in premenopausal women newly diagnosed with early-stage hormone-responsive breast cancer. The study is sponsored by Atossa Therapeutics, which has announced plans to submit an application for regulatory approval from the Food and Drug Administration (FDA) in 2026.

This research represents a promising advancement in the treatment of breast cancer, potentially paving the way for improved outcomes for patients who previously faced limited options. As the scientific community continues to explore this area, the hope is that these findings will lead to more effective therapies and better survival rates for individuals affected by this disease.